RTP Mobile Logo
International Second Opinion — Part II: Case-Based Discussions Focused on the Management of Multiple Myeloma
Released March 2013

Proceedings from Part II of a 2-part satellite symposia series during the 54th ASH Annual Meeting. Including perspectives from Drs Sergio Giralt, A Keith Stewart, Ravi Vij, Donna E Reece and Meletios A Dimopoulos. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

    OVERVIEW OF ACTIVITY


    Taken together, it is estimated that approximately 148,040 new lymphoid and myeloid cancer cases were identified in the United States in the year 2012, and 54,380 individuals died from these diseases. Of importance, currently more than 50 drug products are labeled for use in the management of hematologic cancers, with more than 60 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a CME symposium during the 54th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology on cases provided by an international panel of community oncologists from the United States, India, Italy and Spain to frame a relevant discussion of the optimal management of MM. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for MM.

    LEARNING OBJECTIVES
    • Appraise recent data on therapeutic advances and changing practice standards in MM, and integrate this information, as appropriate, into current clinical care.
    • Use prognostic and predictive clinical and molecular markers to aid in treatment decision-making for MM.
    • Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
    • Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.
    • Recall new data with investigational agents demonstrating promising activity in MM.
    • Assess ongoing clinical trials evaluating innovative investigational approaches for MM, and obtain consent from appropriate patients for study participation.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT


    CME credit is no longer available for this issue



    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY
    — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Sergio Giralt, MD
    Chief, Adult Bone Marrow Transplant Service
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Advisory Committee and Speakers Bureau: Celgene Corporation, Genzyme Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Educational Material Prep: Novartis Pharmaceuticals Corporation.

    A Keith Stewart, MBChB
    Dean for Research, Mayo Clinic in Arizona
    Consultant, Division of Hematology/Oncology
    Vasek and Anna Maria Polak Professorship in Cancer Research
    Scottsdale, Arizona

    Advisory Committee: Amgen Inc, Celgene Corporation; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Contracted Research: Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

    Ravi Vij, MD
    Associate Professor of Medicine
    Washington University School of Medicine
    Section of Stem Cell Transplant and Leukemia
    Division of Medical Oncology
    St Louis, Missouri

    Consulting Agreements: Abbott Laboratories, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals Inc; Contracted Research: Celgene Corporation, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Cephalon Inc, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

    Donna E Reece, MD
    Professor of Medicine
    Director, Program for Multiple Myeloma and Related Diseases
    Princess Margaret Hospital
    Toronto, Ontario

    Advisory Committee: Celgene Corporation; Consulting Agreements: Celgene Corporation, Janssen Pharmaceuticals Inc; Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation.

    Meletios A Dimopoulos, MD
    Chairman, Department of Medical Therapeutics
    University of Athens School of Medicine
    Athens, Greece

    Advisory Committee: Celgene Corporation, Novartis Pharmaceuticals Corporation; Consulting Agreements: Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.

    CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Warren S Brenner, MBBCh

    Center for Hematology/Oncology
    Lynn Cancer Institute
    Boca Raton, Florida

    Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company; Stock Ownership: Celgene Corporation.

    Ramón García-Sanz, MD, PhD
    Department of Hematology
    Hospital Universitario de Salamanca
    Salamanca, Spain

    No real or apparent conflicts of interest to disclose.

    Alberto Grossi, MD
    Unit of Hematology
    Istituto Fiorentino di Cura e Assistenza (IFCA)
    Florence, Italy 

    No real or apparent conflicts of interest to disclose.

    Vineet Gupta, MD
    Principal Consultant, Medical Oncology
    Max Super Speciality Hospital
    Delhi, India

    No real or apparent conflicts of interest to disclose.

    Elizabeth D Simmons, MD
    Physician Lead of Service, Hematology/Medical Oncology
    Kaiser Permanente
    Bellflower, California
    Volunteer Faculty
    Harbor-UCLA Medical Center, Hematology
    Torrance, California

    No real or apparent conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Gilead Sciences Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

Acknowledge and close

Watch video
(WiFi is recommended for best performance):

Introduction: Dr Love
Module 1:
Dr Giralt -
Management of Younger, Transplant-Eligible Pts
Module 2:
Dr Stewart –
Maintenance Rx; Predictors of Response
Module 3:
Dr Vij –
Management of Older, Nontransplant-Eligible Pts
Module 4:
Dr Reece –
Treatment of Relapsed/Refractory MM
Module 5:
Dr Dimopoulos –
Use of Bone-Targeted Agents